2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Sunday, November 8, 2015

2:30PM-4:00PM: Abstract Number: 953

Effectiveness of a Progressive Resistence Strength Programme on Hand Osteoarthritis: A Randomized Crontrolled Trial

Osteoarthritis - Clinical Aspects: Treatments and Epidemiology

2:30PM-4:00PM: Abstract Number: 970

Efficacy and Safety of Sarilumab in Combination with Csdmards in Patients with Active Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant of Anti–TNF-Î± Therapy: Results from a Phase 3 Study

Rheumatoid Arthritis-Small Molecules, Biologics and Gene Therapy I: Biologics

2:30PM-4:00PM: Abstract Number: 960

Efficacy of Canakinumab in Systemic Juvenile Idiopathic Arthritis Patients Previously Exposed to Biologics

Pediatric Rheumatology - Clinical and Therapeutic Aspects I: Juvenile Idiopathic Arthritis

2:30PM-4:00PM: Abstract Number: 983

ERAP1 Deficiency Protects HLA-B27 Transgenic Rats from Arthritis

Spondylarthropathies Psoriatic Arthritis - Pathogenesis, Etiology

2:30PM-4:00PM: Abstract Number: 930

Evaluation of Temporomandibular Joint Arthritis with Ultrasound in Juvenile Idiopathic Arthritis

Imaging of Rheumatic Diseases I: Ultrasound

2:30PM-4:00PM: Abstract Number: 922

Factors Associated with Performance on Quality Measures Pertaining to Assessment of Disease Activity in Juvenile Idiopathic Arthritis

Health Services Research I: Digital Health and Patient, Provider Factors in Rheumatic Disease

2:30PM-4:00PM: Abstract Number: 988

Factors Associated with Renal Remission, Relapse and Long-Term Renal Function Decline in Lupus Nephritis Treated with Combined Prednisolone and Mycophenolate Mofetil (MMF) or Tacrolimus (Tac)

Systemic Lupus Erythematosus - Clinical Aspects and Treatment I: Epidemiology and Prognosis

2:30PM-4:00PM: Abstract Number: 993

Failure in Nutrient Sensing Supports mTOR Hyperactivity and Proinflammatory Functions in T Cells from Patients with Rheumatoid Arthritis

T cell Biology and Targets in Autoimmune Disease I

2:30PM-4:00PM: Abstract Number: 997

Feasibility and Influential Factors in Performing Self-Evaluation of DAS28 with Smart System of Disease Management (SSDM) By RA Patient in China

ARHP I: Exemplary Abstracts

2:30PM-4:00PM: Abstract Number: 979

HLA Class I Genes As Susceptibility Markers of Psoriatic Arthritis in Patients with Psoriasis – a Meta-Analysis

Spondylarthropathies Psoriatic Arthritis - Pathogenesis, Etiology

2:30PM-4:00PM: Abstract Number: 936

IL-1 Receptor Antagonist Maintains Intestinal Microbial Homeostasis to Prevent Overt Toll-like Receptor 4-Dependent Intestinal Th17 Differentiation and Autoimmune Arthritis

Innate Immunity and Rheumatic Disease

2:30PM-4:00PM: Abstract Number: 985

Improved Survival in Systemic Lupus Erythematosus: A Population-Based Study

Systemic Lupus Erythematosus - Clinical Aspects and Treatment I: Epidemiology and Prognosis

2:30PM-4:00PM: Abstract Number: 950

In a Two-Year Double-Blind Randomized Controlled Multicenter Study, Chondroitin Sulfate Was Significantly Superior to Celecoxib at Reducing Cartilage Loss with Similar Efficacy at Reducing Disease Symptoms in Knee Osteoarthritis Patients

Osteoarthritis - Clinical Aspects: Treatments and Epidemiology

2:30PM-4:00PM: Abstract Number: 995

In Rheumatoid Arthritis Only a Few Expanded T-Cell Clones Dominate in Joint Inflammation: A Study in Seven RA Patients Undergoing Paired Synovial Tissue Biopsies in Multiple Joints

T cell Biology and Targets in Autoimmune Disease I

2:30PM-4:00PM: Abstract Number: 966

In Rheumatoid Arthritis, Smoking Is Not Associated with Anti-Citrullinated Protein Antibodies per Se, but with the Concurrent Presence of Rheumatoid Factor, Anti-Citrullinated Protein Antibodies and Anti-Carbamylated Protein Antibodies

Rheumatoid Arthritis - Human Etiology and Pathogenesis I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].